Skip to main content

Table 2 Differentially methylated regions (DMRs) with fold change values above 3.5 after comparing individuals with MDS who progressed to AML against individuals with MDS who did not

From: Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response

Chromosome

Start

End

Fold Change

Genomic loci description

Genomic annotation

chr6

169,966,466

169,968,275

9.52

CpG-island

CpG43837

chr1

247,170,879

247,172,787

5.79

CpG-island

CpG4368

chr1

247,170,879

247,172,787

5.79

TSS

ZNF124

chr1

247,170,879

247,172,787

5.79

postTSS1KB-TES

ZNF124

chr4

186,433,489

186,435,606

5.27

postTSS1KB-TES

F11-AS1

chr4

186,433,489

186,435,606

5.27

postTSS1KB-TES

RP11-215A19.2

chr10

133,292,034

133,292,157

5.04

CpG-island

CpG6468

chr10

133,292,034

133,292,157

5.04

postTSS1KB-TES

TUBGCP2

chr1

247,126,037

247,127,603

4.89

CpG-island

CpG4367

chr1

247,126,037

247,127,603

4.89

postTSS1KB-TES

ZNF124

chr10

75,405,211

75,405,359

3.73

CpG-island

CpG5460

chr10

75,405,211

75,405,359

3.73

postTSS1KB-TES

ZNF503-AS2

  1. Chromosome loci of the DMRs, fold change and genomic annotation with regard to the identified DMRs. TSS Transcription Start Site; TES Transcription End Site; postTSS1KB-TES, indicates the region starting at 1 Kb after the TSS until the TES thus corresponding to the gene body without promoter region